6533b832fe1ef96bd129ada8
RESEARCH PRODUCT
High susceptibility of MDR and XDR Gram-negative pathogens to biphenyl-diacetylene-based difluoromethyl-allo-threonyl-hydroxamate LpxC inhibitors
Jean-marie PagèsRené CourcolPei ZhouMarie TitecatNadine LemaîtreThierry LambertEric J. TooneAudrey CharletFlorent SebbaneDidier HocquetChul-jin LeeXiaofei Liangsubject
Acinetobacter baumanniiThreonine0301 basic medicineMicrobiology (medical)Klebsiella pneumoniaemedicine.drug_class030106 microbiologyAntibioticsMicrobial Sensitivity TestsHydroxamic Acidsmedicine.disease_causebeta-LactamasesAmidohydrolasesMicrobiology03 medical and health sciencesBacterial ProteinsEnterobacteriaceae[ SDV.MP ] Life Sciences [q-bio]/Microbiology and ParasitologyDrug Resistance Multiple BacterialGram-Negative BacteriaEscherichia colipolycyclic compoundsmedicineHumansPharmacology (medical)Enzyme InhibitorsOriginal ResearchPharmacologybiologyPseudomonas aeruginosaEnterobacteriaceae Infectionsbiochemical phenomena metabolism and nutritionbacterial infections and mycosesAntimicrobialbiology.organism_classificationEnterobacteriaceaeAnti-Bacterial Agents3. Good healthAcinetobacter baumanniiCiprofloxacinKlebsiella pneumoniae[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyInfectious DiseasesAmikacinPseudomonas aeruginosalipids (amino acids peptides and proteins)medicine.drugdescription
International audience; Inhibitors of uridine diphosphate-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC, which catalyses the first, irreversible step in lipid A biosynthesis) are a promising new class of antibiotics against Gram-negative bacteria. The objectives of the present study were to: (i) compare the antibiotic activities of three LpxC inhibitors (LPC-058, LPC-011 and LPC-087) and the reference inhibitor CHIR-090 against Gram-negative bacilli (including MDR and XDR isolates); and (ii) investigate the effect of combining these inhibitors with conventional antibiotics.MethodsMICs were determined for 369 clinical isolates (234 Enterobacteriaceae and 135 non-fermentative Gram-negative bacilli). Time–kill assays with LPC-058 were performed on four MDR/XDR strains, including Escherichia coli producing CTX-M-15 ESBL and Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii producing KPC-2, VIM-1 and OXA-23 carbapenemases, respectively.ResultsLPC-058 was the most potent antibiotic and displayed the broadest spectrum of antimicrobial activity, with MIC90 values for Enterobacteriaceae, P. aeruginosa, Burkholderia cepacia and A. baumannii of 0.12, 0.5, 1 and 1 mg/L, respectively. LPC-058 was bactericidal at 1× or 2× MIC against CTX-M-15, KPC-2 and VIM-1 carbapenemase-producing strains and bacteriostatic at ≤4× MIC against OXA-23 carbapenemase-producing A. baumannii. Combinations of LPC-058 with β-lactams, amikacin and ciprofloxacin were synergistic against these strains, albeit in a species-dependent manner. LPC-058's high efficacy was attributed to the presence of the difluoromethyl-allo-threonyl head group and a linear biphenyl-diacetylene tail group.ConclusionsThese in vitro data highlight the therapeutic potential of the new LpxC inhibitor LPC-058 against MDR/XDR strains and set the stage for subsequent in vivo studies.
year | journal | country | edition | language |
---|---|---|---|---|
2016-01-01 | Journal of Antimicrobial Chemotherapy |